25th week of 2019 patent applcation highlights part 10 |
Patent application number | Title | Published |
20190183932 | COMPOSITIONS AND METHODS FOR INHIBITING T CELL EXHAUSTION - The present invention relates to T cell compositions and methods of using the same in the context of therapy and treatment. In particular, the invention provides T cells that are modified (e.g., genetically and/or functionally) to maintain functionality under conditions in which unmodified T cells display exhaustion. Compositions and methods disclosed herein find use in preventing exhaustion of engineered (e.g., chimeric antigen receptor (CAR) T cells) as well as non-engineered T cells thereby enhancing T cell function (e.g., activity against cancer or infectious disease). | 2019-06-20 |
20190183933 | BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS - Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided. | 2019-06-20 |
20190183934 | TREATMENT OF DISEASE BASED ON IMMUNE CELL SEQUENCING - The present invention relates to treatment of disease, including treatment of antibody-mediated autoimmune disorders, as well as treatment of other conditions in which antibody therapeutics can be beneficial for targeting destruction of foreign or malignant cells. | 2019-06-20 |
20190183935 | COMPOSITIONS AND METHODS FOR RAPID CLONING OF T-CELL RECEPTORS - Provided are methods, compositions, recombinant DNA molecules, and kits for cloning T cell receptors (TCRs). The methods facilitate construction of TCR expression libraries from biological samples containing antigen-specific T cells, including but not limited to tumor biopsies, including frozen tumor biopsies. Peripheral T cells that were engineered with library-derived TCR genes show potent therapeutic anti-tumor effects. The method can be performed using any sample that contains T cells, and can be performed with oligoclonal populations of T cells, such as T cells that have infiltrated a tumor. Primer combinations for first strand cDNA synthesis, second strand cDNA synthesis, and for cloning a plurality of distinct TCR β and TCR α chains into a plurality of vectors are provided. Cells containing the vectors are provided, as are kits for use in rapid cloning of the TCR β and TCR α chains. | 2019-06-20 |
20190183936 | CONSTITUTIVELY ACTIVE CYTOKINE RECEPTORS FOR CELL THERAPY - Embodiments of the disclosure include methods and compositions for enhancing expansion of immune cells for immunotherapy. In particular embodiments, immune cells, such as T-cells, express a constitutively active cytokine receptor in which the transmembrane and endodomains are able to provide an activating signal separately from any input to the corresponding exodomain to which they are operably linked. In specific embodiments, the transmembrane and endodomain from IL-7Rα is utilized with the exodomain of CD34. | 2019-06-20 |
20190183937 | LIFE EXTENSION AGENT - The present invention relates to a life extension agent containing CD24-negative mesenchymal stem cells and the treatment of dementia, cerebral infarction, spinal cord injury and the like using the life extension agent. | 2019-06-20 |
20190183938 | Provision of a Therapeutically Active Cell Product - A therapeutically active cell product and an ex vivo method for preparing it from a tissue donation are provided. The method comprises an in vitro immuno-depletion of hematopoietic stem cells and cells of hematopoietic lineage. The therapeutically active cell product obtained by the method comprises a portion of non-hematopoietic stem cells comprising non-hematopoietic progenitor [stem] cells, multipotent stem cells and/or pluripotent stem cells. Further aspects include the cell product for therapeutic use, in particular for the treatment of autoimmune and/or neurological disease. | 2019-06-20 |
20190183939 | CELL THERAPY USING MIDBRAIN-TYPE NEURAL STEM CELLS TREATED WITH VITAMIN C - The present invention relates to a cell therapeutic agent including ventral midbrain-type neural stem cells (VM-NSCs) obtained by treating vitamin C during cell expansion to prevent or treat a neurological disease. Since the vitamin C treatment during NSC expansion prevents the loss of therapeutic function-related NSC characteristics, such as expression of midbrain-specific factors, in the cell expansion, a safe, simple and effective method for mass-producing a cell therapeutic agent with excellent therapeutic functions is provided. | 2019-06-20 |
20190183940 | IDENTIFICATION AND USES OF VASCULATURE FORMING PROGENITOR CELLS AND PROGENITOR CELL COMBINATIONS - Methods, compositions, and kits for producing functional blood vessels, and progenitors thereof are provided. Human disorders of the vascular system are treated by reconstitution of functional vessels in vivo through co-transplantation with supporting niche stromal cells for treatment of ischemic injury in the peripheral limbs and heart. The cell populations of the invention, when engrafted into a recipient, anastomose with host vasculature and regenerate functional blood vessels. | 2019-06-20 |
20190183941 | NOVEL BACTERIAL SPECIES | 2019-06-20 |
20190183942 | TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL MICROFLORA - Provided herein are methods of treatment and/or prevention of cancer by manipulation of commensal microflora. In particular, the amount, identity, presence, and/or ratio of microflora (e.g., gut microflora) in a subject is manipulated to facilitate one or more co-treatments. | 2019-06-20 |
20190183943 | COMPOSITION, FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH, COMPRISING STRAINS SHOWING LIPOLYSIS EFFECT - The present invention relates to a novel | 2019-06-20 |
20190183944 | BABY FOOD COMPOSITION COMPRISING VIABLE PROPIONIC ACID-PRODUCING BACTERIA - The present invention relates to compositions, particularly baby food compositions, including living propionic acid-producing bacteria, preferably lactate-utilizing propionic acid-producing bacteria, their manufacture and use in the treatment of digestive diseases, particularly for treatment of infantile colic. | 2019-06-20 |
20190183945 | NOVEL VIBRIO ANGUILLARUM BACTERIOPHAGE VIB-ANP-1 AND USE THEREOF FOR INHIBITING PROLIFERATION OF VIBRIO ANGUILLARUM BACTERIA - The present invention relates to Siphoviridae bacteriophage Vib-ANP-1 (accession number KCTC 13075BP) having the ability to specifically kill | 2019-06-20 |
20190183946 | ONCOLYTIC ADENOVIRUSES FOR CANCER TREATMENT - The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer. | 2019-06-20 |
20190183947 | ONCOLYTIC VACCINIA VIRUS MUTANTS AND USING SAME FOR CANCER TREATMENT - Methods utilizing vaccinia virus with mutations in E3L to infect and cause lysis of cancer cells with less than normal protein levels of RIP3 and/or DAI. Further, the disclosed vaccinia viruses with mutations in E3L cannot replicate well in cells with normal expression or upregulation of RIP3, DAI, and/or MLKL. | 2019-06-20 |
20190183948 | USE OF BCL-XL INHIBITOR AND ONCOLYTIC VIRUS IN PREPARATION OF ANTITUMOR DRUG - This invention belongs to the field of biomedicine and relates to use of Bcl-xL inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that the Bcl-xL inhibitor can be used as an anti-tumor synergist for oncolytic virus. The present invention also relates to a pharmaceutical composition comprising Bcl-xL inhibitor and oncolytic virus, a pharmaceutical kit comprising Bcl-xL inhibitor and oncolytic virus, and use of Bcl-xL inhibitor and oncolytic virus for treating tumors, especially, tumors that are not sensitive to the oncolytic virus. | 2019-06-20 |
20190183949 | APPLICATION FOR WATER EXTRACT OF PLANT OF GRACILARIACEAE OR FERMENT THEREOF AND PHARMACEUTICAL COMPOSITION AND/OR HEALTH FOOD FOR TREATING AND/OR ALLEVIATING NERVOUS DISEASES - The present disclosure provides a method for treating and/or alleviating nervous diseases, including: administering an effective amount of a water extract of a plant of Gracilariaceae or a ferment thereof to a subject in need thereof to treat and/or alleviate a nervous disease thereof, wherein the ferment of the water extract of a plant of Gracilariaceae is a lactic acid bacteria ferment. | 2019-06-20 |
20190183950 | COMMENSAL FUNGI AND COMPONENTS THEREOF FOR USE IN MODULATING IMMUNE RESPONSES - Compositions and methods of modulating immune responses (e.g., immune responses mediated by Th17 CD4 | 2019-06-20 |
20190183951 | Hemp Leaf Chew Composition and Method for Producing - A method for preparing a hemp leaf chew includes decarboxylating hemp and then mixing decarboxylated hemp with a syrup to create the hemp leaf chew. The hemp leaf chew is meant to be chewed by a user similar to chewing tobacco. The method may further include dosing the hemp leaf chew with THC. | 2019-06-20 |
20190183952 | METHODS FOR PREPARING ACTIVE EXTRACT AND APPLICATION THEREOF - Disclosed is a method for preparing an active | 2019-06-20 |
20190183953 | IMMUNOLOGICALLY ACTIVE PHYTO-MIXTURE AND ITS USE IN THE PREVENTION AND IN A METHOD FOR TREATMENT OF EFFLORESCENCES - The present invention relates to an immunologically active phyto-mixture comprising at least one plant extract selected from the family (a) Asteraceae, (b) Verbenaceae, and/or (c) Burseraceae, preferably at least one plant extract from the genus (a) | 2019-06-20 |
20190183954 | HERBAL PREPARATION FOR ACCELERATING WOUNDS AND SKIN INFLAMMATIONS HEALING, ESPECIALLY FOR TREATMENT OF HERPES AND ACNE, AND ITS APPLICATION - An object of the application is a herbal preparation which can be applied in a wound and skin inflammation healing, especially in treatment of herpes and acne, wherein the herbal preparation is characterized in that the preparation contents of emulsified or suspended in an organic medium extract of | 2019-06-20 |
20190183955 | COMPOSITION AND METHOD FOR TREATING PLANTAR FASCIITIS IN HUMANS - A topical, non-prescription formulation of essential oils combined with skin permeation enhancers for the clinical treatment of plantar fasciitis in humans. The formulation may exclude black pepper essential oil. The present compositions and methods relate to a method for treating a disorder chosen from plantar fasciitis, bursitis, or arthritis in humans in a patient in need thereof, comprising administering to the patient compositions having a therapeutically effective amount of a combination of isoprenoidal essential oils, for example, Tea Tree Oil and Clove Bud Oil, in combination with a skin permeation enhancer, such as DMSO, the administration comprising contacting an affected area of skin of the patient with the composition. | 2019-06-20 |
20190183956 | USE OF A CLOVE OIL FRACTION - The present invention relates to a method and composition for treating inflammatory conditions of the animal body using a clove oil fraction, particularly a fraction that remains after removal of eugenol. Such a composition can be used as an analgesic and an anti-inflammatory. | 2019-06-20 |
20190183957 | COMPOSITION FOR PREVENTING AND TREATING PREMATURE OVARIAN FAILURE, CONTAINING EVODIA RUTAECARPA BENTHAM EXTRACT HAVING PROTECTIVE ACTIVITY AGAINST OVOTOXICITY - The present invention relates to a pharmaceutical composition for preventing or treating ovotoxicity, and more specifically, to a pharmaceutical composition for preventing or treating ovotoxicity, containing an | 2019-06-20 |
20190183958 | GRAPE EXTRACTS AND METHODS OF RELATING THERETO - Provided are liquid and powder grape extracts having elevated phenolic content. The extracts can be made from grape seeds, grape skins, or a combination thereof. In some instances, extracts may be blends of grape seed extracts and grape skin extracts. Methods of manufacturing such extracts area also provided. Such methods involve controlled temperature conditions to increase yield of phenolic compounds in the extracts. Methods of using the extraction for treating subjects are also provided, including treatment of cancer and end-organ damage relating to hypertension. | 2019-06-20 |
20190183959 | COMPOSITIONS, KITS AND METHODS FOR TREATING TYPE II DIABETES MELLITUS - Disclosed herein are methods for treating type II diabetes mellitus. In particular, the present invention relates to methods of using an extract of | 2019-06-20 |
20190183960 | METHOD TO TREAT ASTHMA AND AIRWAY ALLERGY USING CYCLO TYROSINE-VALINE AND RELATED COMPOUNDS - The present invention provides a method to treat asthma and airway allergy by administering the dipeptide cyclo tyrosine-valine or a related cyclodipeptide compound to a subject in need thereof. Cyclo tyrosine-valine or the related cyclodipeptide compound reduces Th2 cell activation, airway hyperresponsiveness, accumulation of immune cells in bronchoalveolar fluid, and allergen-specific antibody production in an animal or human subject. The compound can therefore be used to treat asthma and airway allergy. | 2019-06-20 |
20190183961 | GLUTAMINE FOR PRESERVING, IMPROVING OR RESTORING KIDNEY FUNCTION - The present disclosure relates to L-glutamine for use in preserving, improving or restoring kidney function or for decelerating and/or attenuating a decline in kidney function. | 2019-06-20 |
20190183962 | ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO - Provided herein are dosage forms and kits comprising angiotensin II that are suitable for the treatment of low blood pressure. In particular, dosage forms and kits that facilitate the ability to rapidly prepare angiotensin II for IV infusion into a subject. | 2019-06-20 |
20190183963 | PROCESS FOR THE SYNCHRONIZATION OF OVULATION FOR TIMED BREEDING WITHOUT HEAT DETECTION - A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy. | 2019-06-20 |
20190183964 | FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF - The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function. | 2019-06-20 |
20190183965 | METHODS AND COMPOSITIONS COMPRISING A C-TERMINAL BAX PEPTIDE - In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells. | 2019-06-20 |
20190183966 | THERAPEUTIC VITAMIN D CONJUGATES - The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide. | 2019-06-20 |
20190183967 | COMPOSITIONS AND METHODS FOR TREATING FIBROSIS - The invention provides methods for treating fibrosis and/or cancer in a subject in need thereof. The methods include providing a composition comprising an inhibitor of IL-4/IL-13 receptor function and administering an effective amount of the composition to the subject to treat fibrosis and/or cancer. | 2019-06-20 |
20190183968 | METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS - Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+ cells are provided as well. | 2019-06-20 |
20190183969 | DIAGNOSIS, PREVENTION, AND/OR TREATMENT OF AUTOIMMUNE DISEASES - Compositions, methods, and kits are for the diagnosis, prevention and/or treatment of autoimmune diseases by detecting, targeting, and/or eliminating epitope-specific autoimmune cells. The compositions include a conjugate of an epitope and an agent that allows for detecting, targeting, and/or eliminating epitope-specific autoimmune cells. | 2019-06-20 |
20190183970 | METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE - Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease. | 2019-06-20 |
20190183971 | ISCHEMIA/REPERFUSION INJURY - Compositions for treatment and prevention of ischemia/reperfusion injury include agents that increase levels of the Bcl2-associated athanogene 3 (BAG3). The compositions are administered to a subject suffering from ischemia/reperfusion injury or who is at risk for ischemia/reperfusion injury. | 2019-06-20 |
20190183972 | COMBINATION OF RAMUCIRUMAB AND PEMBROLIZUMAB FOR THE TREATMENT OF CERTAIN CANCERS - The present disclosure relates to a combination of ramucirumab and pembrolizumab and methods of using the combination to treat certain disorders, such as non-small cell lung cancer, urothelial cancer, biliary tract cancer, and advanced gastric or gastroesophageal junction adenocarcinoma. | 2019-06-20 |
20190183973 | METHODS FOR PREVENTING OR TREATING ALLERGY BY ADMINISTERING AN IL-4R ANTAGONIST - The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody. | 2019-06-20 |
20190183974 | Compositions and Methods of Use for Treating Metabolic Disorders - Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided. | 2019-06-20 |
20190183975 | HUMAN NOTCH1 BASED FUSION PROTEINS AS DECOY INHIBITORS OF JAGGED-NOTCH SIGNALING AND DLL-NOTCH SIGNALING - This invention provides a fusion protein, the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids in: (a) an extracellular domain of a human Notch1 receptor protein, followed by (b) an Fc portion of an antibody, wherein the extracellular domain of the human Notch1 receptor protein (i) commences with the amino acid present at the N-terminus of EGF-like repeat 10 and (ii) extends to and includes the C-terminal amino acid of EGF-like repeat 18 or 20. Also provided is a composition comprising the any of the fusion proteins of this invention and a pharmaceutically acceptable carrier, a method of treating a subject suffering from age-related macular degeneration (AMD), diabetic retinopathy, or cancer which comprises administering to the subject any of the compositions of this invention in an amount effective to treat the subject's cancer. | 2019-06-20 |
20190183976 | GPCR HETEROMER INHIBITORS AND USES THEREOF - This invention relates to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers (CXCR4-GPCR heteromers) associated with cancers, where CXCR4 forms a functional heteromer with other G protein-coupled receptors (GPCRx). More specifically, this invention relates to GPCRx that form heteromers with CXCR4, which upon co-stimulation with CXCR4 agonists and GPCRx agonists leads to enhanced signaling downstream of CXCR4. This invention also provides for the use of inhibitors of the interacting GPCR partner of the CXCR4-GPCRx heteromer or CXCR4-GPCRx heteromer-specific inhibitors including inhibitors of the formation of the CXCR4-GPCRx heteromer and CXCR4-GPCRx heteromer-specific antibodies, and in the diagnosis and/or therapy for cancer. | 2019-06-20 |
20190183977 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Cancer is a complex group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Described herein are compositions and methods for the treatment of cancer. | 2019-06-20 |
20190183978 | Long-Acting Peptide Analogs - Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo. | 2019-06-20 |
20190183979 | INSULIN CONTAINING PHARMACEUTICAL COMPOSITIONS - The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy. | 2019-06-20 |
20190183980 | INSULIN GLARGINE - There is provided inter alia an aqueous solution composition comprising insulin glargine as an active ingredient and an amino acid selected from aspartic acid and glutamic acid as a stabilising agent, wherein the amino acid is present at a concentration of 1-50 mM. | 2019-06-20 |
20190183981 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2019-06-20 |
20190183982 | POLYMERIC RED BLOOD CELL-LIKE PARTICLES - Disclosed herein are synthetic particles that are shaped like red blood cells. The particles include pectin and oligochitosan and optionally a bioactive agent. In addition, methods of making the synthetic particles via electrospray techniques are provided. | 2019-06-20 |
20190183983 | MYELOPEROXIDASE COMPOSITIONS AND METHODS FOR INHIBITION OF LIPOPOLYSACCHARIDES AND LIPID A - Compositions comprising a combination of myeloperoxidase and a peroxide-producing oxidase and methods of using the compositions to inactivate gram negative bacterial lipopolysaccharides and lipid A endotoxin are provided. | 2019-06-20 |
20190183984 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF HEPARAN N-SULFATASE - The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A. | 2019-06-20 |
20190183985 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS - Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly. | 2019-06-20 |
20190183986 | CELL MEMBRANE TRANSLOCATION OF REGULATED SNARE INHIBITORS, COMPOSITIONS THEREFOR, AND METHODS FOR TREATMENT OF DISEASE - Compositions and methods of modulating cellular function and treatment of disease in mammals comprising locally administering a regulated SNARE inhibitor and a translocating agent to the mammal. Regulated SNARE inhibitors include clostridial neurotoxins, tetanus neurotoxin and their free light chain portions and IgA protease. Translocating agents include acids, encapsulating vectors, and transduction domains. | 2019-06-20 |
20190183987 | NEUROTOXINS FOR USE IN MINIMIZING SCARRING - Methods to minimize scarring during the wound healing process are described. Methods to improve appearance of a scar that forms over a wound are also described. The methods comprise administering a therapeutically effective amount of botulinum toxin subtype E (BoNT/E) in the proximity of a wound. | 2019-06-20 |
20190183988 | NEUROTOXIN FORMULATION - The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins. | 2019-06-20 |
20190183989 | USE OF SERINE PROTEASE INHIBITORS IN THE TREATMENT OF SKIN DISEASES - This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration to a subject in need thereof of a therapeutically effective amount of a Serine protease inhibitor. | 2019-06-20 |
20190183990 | METHOD OF TREATMENT OF SCHIZOPHRENIFORM DISORDER - Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder. | 2019-06-20 |
20190183991 | METHOD OF PREVENTING ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY - The invention relates to a method for determining a dosing scheme for the treatment of hereditary angioedema and/or the prevention of hereditary angioedema attacks with C1 esterase inhibitor to optimize treatment response in an individual patient. Accordingly, the present invention provides means for determining individual C1 esterase inhibitor dosing schemes that result in an optimal treatment/prevention outcome. | 2019-06-20 |
20190183992 | PROGRAMMING OF CELLS FOR TOLEROGENIC THERAPIES - Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease. | 2019-06-20 |
20190183993 | REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF - The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention. | 2019-06-20 |
20190183994 | REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF - The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention. | 2019-06-20 |
20190183995 | METHOD OF EXPANDING NK CELL AND COMPOSITION FOR CULTURING - Provided are a method of ex-vivo culture of natural killer (NK) cells by treating the cells with a reactive oxygen species (ROS) inhibitor and/or a p53 protein inhibitor; and a composition comprising the cultured NK cells. By reducing the activity of ROS and p53 proteins during ex-vivo culture, NK cells may have achieved greater expansion efficiency without altering their anti-tumor cytotoxicity. | 2019-06-20 |
20190183996 | PROCESS FOR THE PRODUCTION OF A DNA VACCINE FOR CANCER IMMUNOTHERAPY - The present invention relates to a method for producing a DNA vaccine for cancer immunotherapy comprising at least the steps of (a) transforming an attenuated strain of | 2019-06-20 |
20190183997 | IDENTIFICATION AND PRODUCTION OF HIGH AFFINITY IGM ANTIBODIES AND DERIVATIVES THEREOF - Provided herein are methods of sorting antigen-specific IgM memory B cells (MBCs), compositions and methods comprising such antigen-specific IgM MBCs, and recombinant antibody or antigen-binding fragments isolated from such antigen-specific IgM MBCs. As demonstrated herein, IgM and IgD MBCs are unique populations of cells with distinct phenotypic, functional and survival properties. Accordingly, the antigen-specific IgM MBCs and antibodies and antigen-binding fragments derived from these cells described herein are useful in therapeutic applications in vaccine strategies and treatment of infectious diseases. | 2019-06-20 |
20190183998 | Mycobacterium Antigenic Composition - Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided. | 2019-06-20 |
20190183999 | DEVELOPMENTS IN MENINGOCOCCAL OUTER MEMBRANE VESICLES - A first aspect of the invention provides meningococcal outer membrane vesicles in which NHBA is over-expressed. A second aspect of the invention provides meningococcal outer membrane vesicles in which NadA is over-expressed. A third aspect of the invention provides a panel of bacterial strains, each member of which is isogenic except for a single gene which in each strain encodes a different variant antigen of interest. | 2019-06-20 |
20190184000 | RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS STRAINS COMPRISING NS1 AND NS2 GENE SHIFTS - Reported herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype in which the native positions of the NS1 and/or NS2 genes in the RSV genome are shifted to a higher position, that is at positions that are more distal to the promoter. The changes in the gene positions may be present in combination with mutations at other loci to achieve desired levels of attenuation and immunogenicity. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses. | 2019-06-20 |
20190184001 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE HUMAN PAPILLOMAVIRUS FORMULATIONS - Embodiments of the present invention provide for novel compositions and methods for making and using a thermally stable human papilloma virus (HPV) formulation or other stabilized multimeric virus formulation. Certain embodiments concern lyophilizing HPV formulations in the presence or absence of adjuvants. Other embodiments concern lypophilizing HPV capsomere vaccines in order to increase stability of an immunogenic composition against HPV infection for storage, delivery and use. In yet other embodiments, a single immunogenic composition can include a thermally stable formulation of multiple virus serotypes. | 2019-06-20 |
20190184002 | HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES - The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B. | 2019-06-20 |
20190184003 | COMPOSITIONS AND METHODS COMPRISING MEASLES VIRUS DEFECTIVE INTERFERING PARTICLES FOR THE PREVENTION OF INFECTIOUS DISEASES - The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5′ copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5′ copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and/or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture. | 2019-06-20 |
20190184004 | COMPOSITIONS AND METHODS FOR STABILIZING FLAVIVIRUSES WITH IMPROVED FORMULATIONS - Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods. | 2019-06-20 |
20190184005 | METHOD AND COMPOSITION FOR AMELIORATING AND ABATING SYMPTOMS RESULTING FROM RHEUMATOID ARTHRITIS, FIBROMYALGIA, AND CHRONIC PAIN OF UNKNOWN ORIGIN - The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as ALS, RA, Tremors/Parkinson's Disease, and MS, Alzheimer's disease, ALS, Guillain-Barre syndrome, atherosclerosis, schizophrenia, Tremors/Parkinson's disease, senile dementia, Muscular Dystrophy, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Complex Regional Pain Syndrome, Diabetes, Neuropathic Pain, Spider Arthritis West Nile Virus, Fibromyalgia, Shingles, Gout, Migraine Headaches, Post Polio Syndrome, Central Virus Deafness, Asthma, Chronic Pain Of Unknown Origin and Hepatitis C and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from ALS, RA, MS, Tremors/Parkinson's Disease, and prostate cancer and others realized immediate beneficial results with no side effects. | 2019-06-20 |
20190184006 | ENHANCED IMMUNOGENICITY OF mRNA WITH CO-ENCODED ADJUVANT SEQUENCES - Described herein are in vitro-transcribed (IVT) RNA molecules comprising, a 5′ cap structure, a coding region encoding an antigen polypeptide, an immunostimulatory RNA sequence, and a poly(A) tail. | 2019-06-20 |
20190184007 | AVOIDING NARCOLEPSY RISK IN INFLUENZA VACCINES - The invention provides influenza vaccines and methods which improve the safety of influenza vaccines further, in particular in relation to the risk of causing narcolepsy in adjuvanted vaccines. | 2019-06-20 |
20190184008 | Methods and Compositions for Treating and Preventing HIV - Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40). | 2019-06-20 |
20190184009 | Compositions and Methods for Generating an Immune Response to Hepatitis B Virus - The compositions and methods are described for generating an immune response to a hepatitis B virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a hepatitis B virus, in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus. | 2019-06-20 |
20190184010 | METHODS AND APPARATUS FOR THE DELIVERY OF HEPATITIS B VIRUS (HBV) VACCINES - Methods and apparatus for the reproducible, consistent and efficacious delivery of an HBV vaccine to a subject. The disclosure comprises apparatus for the controlled administration of the HBV vaccine through an orifice to the subject, a plurality of penetrating electrodes arranged with a predetermined spatial relationship relative to the orifice, and an electrical signal generator operatively connected to the electrodes. | 2019-06-20 |
20190184011 | METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV) - Provided herein are Modified Vaccinia Ankara (MVA) vectors and adenovirus vectors encoding HBV antigens. Also provided are methods of enhancing an immune response in a human subject by utilizing the MVA and adenovirus vectors encoding HBV antigens in a prime/boost regimen to the enhance the immune response in the human subject. | 2019-06-20 |
20190184012 | NANOBODY BIOMEDICINE TRANSDERMAL ADMINISTRATION FORMULATION SYSTEM AND PREPARATION METHOD AND USE THEREOF - The invention discloses a transdermal drug delivery scheme for preparing a specific nanobody biopharmaceutical through penetrating skin tissue, and its preparation method and application. Due to biological characteristics such as unstable activity of traditional antibodies or protein macromolecules, the administration of biopharmaceuticals is basically limited to injections. Nanobodies are the smallest units currently known to bind target antigens. The three-dimensional structure of nanobodies determines the relative stability of their structure and biological activity and their biological properties. Nanobodies have the characteristics of high temperature resistance, activity in a certain acid-base environment, good water solubility, and strong tissue penetration. Therefore, by optimizing the formulation of the carrier, the stability of the nanobody and the penetration of the skin tissue can be maintained and increased, so as to achieve a transdermal delivery formulation of the nanobody biopharmaceutical. The transdermal delivery of nanobody can be used for the specific nanobody to play a role in the local application area, and can also be used for the nanobody to penetrate the skin and enter the blood circulation to reach the site of a predetermined lesion. Nanobodies in the transdermal delivery system include specific nanobodies for different lesion targets, such as, but not limited to, dermatological targets, inflammation and rheumatism targets, cancer targets, viral bacteria targets, cardiovascular disease targets, diabetes targets, Alzheimer's disease targets, brain tumor targets. The carrier for transdermal delivery of the nanobody has the advantages of stabilizing the structure and efficacy of the nanobody, releasing the drug via the skin, and having good transdermal effect; the comfort of skin application is high; and the skin irritation and allergic reaction characteristics are basically absent. The carrier system components include, but not limited to, soluble polymer macromolecular carbohydrate matrix, polyethylene glycol (PEG), dextran, polyamino acid, optimized formulation, stirred mixture. The invention discloses a preparation method and application of the transdermal drug delivery system. Transdermal administration is a safe and effective method of administration. Less content of proteolytic enzymes in the skin tissue is conducive to maintaining the stability of such biological drugs. The nanobody biomedical transdermal drug delivery preparation system has the advantages of being non-toxic, stable, controllable, convenient for administration, and easy to operate, etc., and opens up new dosage forms of nanobody biopharmaceuticals, and its application prospect is very broad. | 2019-06-20 |
20190184013 | COMPOSITIONS FOR SELECTIVE HUMORAL RESPONSES AND METHODS OF USE THEREOF - Conjugates of synthetic nanocarriers, complexed with syngeneic (self) proteins adducted with haptens or other poorly immunogenic antigens (antigens of low immunogenicity), elicit selective humoral responses or antibodies against the hapten or antigen and not to self-protein. Compositions include these conjugates, which can be used as vaccines. Methods of making and using them are described herein. In a typical embodiment, a conjugate including a hapten or antigen of low immunogenicity associated with a particular disease (e.g., infection, cancer) can be used as a vaccine by eliciting antibodies that specifically neutralize the hapten or antigen. These hapten (and other poorly immunogenic antigen)-carrying nanocarriers selectively target antigen presenting cells resulting in a strong anti-hapten humoral response, and thus find use in vaccines for cancer (e.g., cancers of lung, cervix, breast, brain, liver pancreas, ovaries, skin, etc.), infectious diseases and inflammatory-mediated diseases, as well as for autoimmune disorders. | 2019-06-20 |
20190184014 | Long-Lived Gadolinium Based Tumor Targeting Imaging and Therapy Agents - Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: | 2019-06-20 |
20190184015 | IRRADIATION TREATMENT OF NEUROLOGICAL SENSATIONS BY PHOTOABLATION - The present invention relates to an approach for the treatment of adverse neurological sensations in a certain body surface area such as the skin, in particular treatment of pain or itching. The invention is based on the finding that administration of a targeting molecule which specifically binds a cell or receptor responsible for the adverse sensation in the respective body surface area of a patient, and which is coupled/conjugated to a photosensitive inhibitor or cytotoxic agent can enable the irradiation dependent ablation of cells responsible for the sensation. This approach allows a targeted and specific treatment of body surface areas by irradiation. Provided are conjugate compounds for use in the photoablation treatment of the invention and pharmaceutical compositions which comprise these compounds. | 2019-06-20 |
20190184016 | OPHTHALMIC COMPOSITION - The present invention relates to ophthalmic compositions for treatment of conditions in the eye. More specifically, the present invention relates to ophthalmic compositions comprising a polyquaternium compound and an anionic polymer. Methods for reducing and/or preventing the incompatibility of polyquaternium compounds with anionic polymers are also disclosed. | 2019-06-20 |
20190184017 | ETANERCEPT FORMULATIONS STABILIZED WITH XYLITOL - The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2019-06-20 |
20190184018 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES - The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below: | 2019-06-20 |
20190184019 | HYDROGEL AND PREPARATION METHOD THEREOF - The invention provides a hydrogel comprising an aqueous chitosan solution and a water-soluble linker agent. The linker agent is a block copolymer composing non-degradable block such as poly(ethylene glycol) and hydrolytic degradable block such as poly(amino acid) and polyester. Both ends of the block copolymer are terminated with active group such as glyoxylic acid, uronic acid and aldehyde benzoic acid. When the two main components are mixed together, the resulting solution will undergo spontaneous gelation at mild condition. The resulting hydrogel is able to retain the stability of biopharmaceuticals fully, therefore, which is qualified to serve as drug vehicles used in vivo and topical applications. | 2019-06-20 |
20190184020 | NOVEL ESTERIFIED CELLULOSE ETHERS OF HIGH MOLECULAR WEIGHT AND HOMOGENEITY - A process for making esterified cellulose ethers which have
| 2019-06-20 |
20190184021 | Porphyrin Compounds and Compositions Useful for Treating Cancer - A porphyrin compound and composition made therefrom comprising a therapeutically effective dose of a porphyrin bound via a linker to an anti-cancer agent useful in treating cancer in a patient in need thereof or to treat cancer cells in-vitro. The compounds and compositions may be delivered by a drug delivery device as disclosed here and be part of a kit. | 2019-06-20 |
20190184022 | BORYL ETHERS, CARBONATES, AND CYCLIC ACETALS AS OXIDATIVELY-TRIGGERED DRUG DELIVERY VEHICLES - A compound, or a pharmaceutically acceptable salt thereof, having a structure of: | 2019-06-20 |
20190184023 | GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME - The present invention provides a glycosaminoglycan derivative in which a group derived from glycosaminoglycan and a group derived from a physiologically active substance having at least one of a carboxy group and a hydroxy group are coupled by covalent bond with a spacer therebetween, in which the spacer is selected in accordance with the decomposition rate of the covalent bond to the group derived from the physiologically active substance. | 2019-06-20 |
20190184024 | RESPONSIVE ELASTIC POLYMERS AND METHODS OF MAKING AND USING SAME - Disclosed herein are functionalized hyaluronic acid (HA), a responsive elastic polymer system comprising functionalized HA, and methods of fabrication and utilization of the same. This polymer system may be used for controlled local or systemic drug delivery release of analgesics, anesthetics, antibiotics and other drugs as well as tissue engineering articles. | 2019-06-20 |
20190184025 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 - The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour). | 2019-06-20 |
20190184026 | LINKER PEPTIDE FOR CONSTRUCTING FUSION PROTEIN - A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin β-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein. Furthermore, a protective effect of a glycosylated side chain CTP can lower the protease sensitivity of the linker peptide, making a linker region of the fusion protein less degradable. | 2019-06-20 |
20190184027 | METHOD OF PREVENTING AND TREATING TYPE 1 DIABETES, ALLOGRAFT REJECTION AND LUNG FIBROSIS (BY TARGETING THE ATP/P2X7R AXIS) - The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling. | 2019-06-20 |
20190184028 | TARGETING WITH FIRBRONECTIN TYPE III LIKE DOMAIN MOLECULES - A fibronectin type III (FN3) domain-nanoparticle or direct conjugate complex containing a polynucleotide molecule, a toxin, polynucleotide molecule or other pharmaceutically active payload is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain with a toxin or nanoparticle containing an active polynucleotide, such as an ASO or siRNA molecule. A fibronectin type III (FN3) domain-nucleic acid conjugate is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain to a nucleic acid (e.g., ASO or siRNA). The nanoparticle complex, nucleic acid conjugate or FN3 domain toxin conjugate may be used in the treatment of diseases and conditions, for example, oncology or auto-immune indications. | 2019-06-20 |
20190184029 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY - The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway. | 2019-06-20 |
20190184030 | Delivery of Urea to Cells of the Macula and Retina Using Liposome Constructs - Provided are liposome constructs for delivery of urea to the vitreoretinal interface of the eye. The liposome constructs are agglomerates of small lamellar vesicles (SUVs) and have a greater density than the vitreal fluid, such that they sink to the back of the eye rather than dispersing throughout the vitreous. | 2019-06-20 |
20190184031 | METHODS OF TREATING COLON CANCER USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY - The present application provides methods of treating a colon cancer (such as advanced and/or metastatic colon cancer) in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, b) an effective amount of anti-VEGF antibody (such as bevacizumab), and c) a therapeutically effective FOLFOX regimen (such as FOLFOX4 or a modified FOLFOX6). | 2019-06-20 |